Shield to develop new sales channels for Afecta
This article was originally published in Clinica
Executive Summary
Shield Diagnostics says that it is in advanced discussion with a number of companies concerning the development of Shield's Afecta Activated Factor XII (AFT) cardiac diagnostic, with the intention of obtaining distribution through two more companies. Shield, which is already in partnership with Abbott Laboratories, is talking to companies that would run Afecta on point-of-care devices as well as those which would add it to a menu of tests on a laboratory analyser.
You may also be interested in...
‘Highly Questionable’ GMP Compliance In Pakistan Prompts New Licensing System
Increased fines and penalties are on the cards for manufacturing facilities that fail to comply with proposed new requirements.
Infographic: 20 Years Of Mega-Deals
The biopharma sector is often accused of a being a slow-moving engine, but a look back over the last 20 years reveals that a lot has changed. In Vivo explores the history of high-impact M&A transactions in the industry between 1999 and 2019.
Belgians To Tackle High Benzodiazepine Use
The Belgian authorities are taking steps to reduce the consumption of benzodiazepine-containing medicines, and have also reiterated the risks associated with the increasing use of opioid medications.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: